

Excellent volume growth for ColdZyme®

Q2

- Net sales reached SEK 4.9 (3.1) million.
- Loss after tax came in at SEK -12.3 (-10.4) thousand.
- Earnings per share were SEK -0.20 (-0.42).
- Cash and cash equivalents were SEK 26.9 (23.4) thousand.

H1

- Net sales increased to SEK 13.3 (10.0) million.
- Loss after tax came in at SEK -20.9 (-19.5) million.
- Earnings per share were SEK -0.47 (-0.78).

Significant events in Q2

- Enzymatica completed its acquisition of Icelandic company Zymetech effective April 1.
- Enzymatica completed its new share issue, raising SEK 60 million before issue expenses.

Financial ratios

(SEK THOUSAND)	Q2 2016	Q2 2015	H1 2016	H1 2015	Full year 2015
Net sales	4.9	3.1	13.3	10.0	27.9
Gross margin, %	63	86	62	76	70
Operating profit/loss	-12.3	-10.4	-20.0	-19.5	-40.5
Cash flow from operating activities	-15.1	-7.9	-19.9	-12.7	-37.7
Average number of employees	22	15	19	15	16

(Zymetech is consolidated in Enzymatica's figures as at April 1, 2016)

CEO statement: With the Zymetech acquisition, we are entering a new phase

We started off the quarter by completing the acquisition of Icelandic company Zymetech, and a new share issue in the amount of SEK 60 million was conducted in May. Enzymatica's stated objective is to establish international sales via renowned partners, and now we are in the process of putting in place the final pieces of a stable foundation. The acquisition of Zymetech gave us a patent family with high strategic significance and know-how relating to the enzyme technology on which ColdZyme is based. We can thus now offer our potential distribution partners both exclusivity and high-class collaboration. Given that Enzymatica and the success of ColdZyme in Sweden are still relatively unknown on the global market, we need to be patient and realize the fact that the internationalization process will take time. This makes it all the more gratifying that we are continuing to increase sales on the markets on which we already operate. Sales in H1 (including Zymetech) were up 32% year-on-year, and increased by 58% in Q2. The number of ColdZyme units sold to end consumers from Swedish pharmacies increased in Q2 by 37%, which indicates a continuing increase in customer demand. As previously announced, it is now important to pitch the success of ColdZyme on the domestic market to potential distribution partners outside of the Nordic region. We are primarily concentrating on the European market, because the product is already CE-marked in the EU. We have also established contacts outside of Europe in parallel

because the time for approval processes in other parts of the world prolongs the time to launch.

Meanwhile, the Zymetech integration process is proceeding according to plan. Enzymatica is making a minor investment in the production plant in Iceland in 2016 to secure access to the enzyme and raise production capacity for future expansion.

We are now in the off season for colds, but I'm confidently looking forward to the second half of the year and to our sales continuing to increase. By the end of the year, we should be able to see the first results of our efforts to sign contracts with new distributors, and we also expect at that time to be able to present the results of our ongoing follow-up study of ColdZyme, which is currently in progress in the UK.


Fredrik Lindberg, CEO

Enzymatica at a glance

Enzymatica AB is a life science company whose business concept is to develop medical devices based on barrier technology and marine enzymes for self care in major market segments. In a short period of time, the company developed ColdZyme®, a unique mouth spray for fighting colds, launched the product in six markets and reached a position over the past winter as one of the most-sold cold products in Swedish pharmacies measured in SEK. Enzymatica has its own sales organization in Scandinavia and collaborates with a contract sales organization in the UK. Enzymatica also sells via distributors in Finland and Spain.

Our development focuses on medical devices for upper respiratory tract infections and oral health. An enzyme from deep-sea fish is a key sub-component in product development.

Enzymatica was founded in 2007, has its head office in Lund, Sweden and has been listed on the Nasdaq First North since June 15, 2015.



ColdZyme is sold both in-house and via distributors and partners in Sweden, Denmark, Norway, Finland, the UK and Spain. A corresponding product is sold in Iceland under the PreCold brand name via acquired company Zymetech.

Q2 performance

In Q2, ColdZyme 7 ml, OneCold, exhibited solid year-on-year volume growth on the Swedish market. ColdZyme (20 and 7 ml) posted 37% volume gains in sales to end consumers from Swedish pharmacies according to up-to-date statistics (Nielsen data). This increase is not fully visible in our own sales figures because the sales increase partially comes from prior replenishment orders.

In Denmark, Enzymatica's Q2 sales performed well year-on-year, while sales in Norway were down. Enzymatica has started the process of finding a distributor for the Norwegian market and has therefore been holding off on continuing marketing initiatives for the time being. Sales of PreCold and skincare products in Iceland performed well in Q2.

Following the solid orders on the Finnish and Spanish markets in Q1, sales were down in Q2, especially given that the cold season is over. The market is expected to pick up again in the fall.

In the UK, efforts to find a powerful distributor for the market are continuing.

Sales, earnings and investments

Q2

Consolidated net sales for Q2 2016 came in at SEK 4.9 (3.1) million – nearly a 60% year-on-year increase. The majority of the sales are from Swedish pharmacies. SEK 1 million of the sales increase came from Zymetech's business.

The gross margin for Q2 was 63% (86%). Enzymatica has experienced

fluctuations in its gross margins between individual quarters as a result of the distribution of sales via its own organization or distributors, the product mix and exchange rates.

Total operating expenses for Q2 amounted to SEK 21.1 (13.6) million. This increase is mainly due to expenses related to the addition of Zymetech's R&D and production operations in Iceland, R&D expenses related to conducting the COLDPREV II clinical trial and non-recurring expenses due to the acquisition of Zymetech.

The group's operating loss was SEK -12.3 (-10.4) million.

Enzymatica capitalizes new development expenditure on an ongoing basis. Capitalized expenses for development projects for Q2 totaled SEK 5.4 (0.5) million.



H1

Consolidated net sales for H1 2016 came in at SEK 13.3 (10.0) million – a 32% year-on-year increase.

The gross margin for the period was 62% (76%).

Total operating expenses for the period were SEK 34.1 (28.9) million. This increase in total operating expenses is mainly due to expenses related to the addition of Zymetech's R&D and production operations in Iceland, R&D expenses related to conducting the COLDPREV II clinical trial and

non-recurring expenses due to the acquisition of Zymetech.

The group's operating loss was SEK -20.0 (-19.5) million.

Enzymatica capitalizes new development expenditure on an ongoing basis. Capitalized expenses for development projects during the period totaled SEK 5.5 (1.7) million.

Seasonal variations

Cold products have a seasonal peak in the winter, while sales level out in the summer months.

Research and development

Strengthening the documentation for the ColdZyme® cold spray is a key part of Enzymatica's R&D activities.

Enzymatica's product development focuses both on in-depth studies aiming to better understand and broaden the use of ColdZyme® and on clinical trials in new areas. In Q1, Enzymatica and Imperial College London signed an agreement to conduct a clinical follow-up study in 2016 aiming to further strengthen the evidence of ColdZyme's quality, safety and efficacy.

The Company has been participating in a four-year research project on chronic oral cavity infections run by Malmö University with funding from Vinnova since the beginning of 2015. The objective is to add more medical devices to the company's range of products in the therapeutic areas of upper respiratory tract infections and oral health.

In addition, work is ongoing to certify the company to ISO standard 13485, a quality management system for medical devices.

Barrier technology with enzyme from deep-sea fish

An enzyme from a deep-sea fish is a key sub-component in Enzymatica's product development efforts for creating effective barriers against viruses and bacteria. The enzyme, which is called cold-adapted trypsin, is formed in the cod's pancreas and becomes hyperactive when it comes into contact with the warm skin and sinuses of humans. Together with glycerol, the enzyme forms a temporary barrier on the skin or sinuses. The barrier makes it more difficult for viruses and bacteria to locally infect cells and cause diseases.

Significant events in Q2

On April 1, Enzymatica completed the acquisition of Zymetech and acquired 99.5% of the shares in Zymetech ehf. for consideration of approximately SEK 76 million.

The new share issue with preemptive rights for the company's shareholders was completed in May. Enzymatica raised approximately SEK 60 million before issue expenses. Several new strategic investors have been brought on board in connection with the issue.

Funding

The Group's available funds at the end of the period totaled SEK 28.2 (29.4) million, of which SEK 26.9 (23.4) million were in cash and cash equivalents and SEK 1.3 (6.0) million in unutilized credit facilities. The proceeds of the new share issue in the amount of SEK 60 million before issue expenses were recognized by the company in May 2016. The quarter was impacted by payments related to transaction and issue expenses, the redemption of non-current loans including factoring and the COLDPREV II clinical trial.

The annual general meeting on 25 May resolved to authorize the board of directors to resolve to raise the company's share capital by issuing a

maximum of 17,500,000 new shares, with or without derogation of the preemptive rights of existing shareholders, on one or more occasions for the time until the next annual general meeting. If necessary, the board thus has the option of raising additional capital for the company's expansion by issuing new shares.

Cash flow from operating activities for the period was SEK -19.9 (-12.7) million. Cash flow from operating activities for Q2 totaled SEK -15.1 (-7.9) million.

Total cash flow for the period amounted to SEK 18.8 (-14.5) million.

Parent company

Parent company sales for the period reached SEK 12.2 (10.0) million. Profit/loss before tax came in at SEK -16.7 (-19.5) million.

Parent company sales for Q2 came in at SEK 3.8 (3.1) million. Profit/loss before tax came in at SEK -8.6 (-10.5) million.

The parent company's investments in property, plant & equipment and intangible assets for the period totaled SEK 5.5 (1.7) million and cash flow was SEK 18.6 (-14.5) thousand.

Please see the consolidated figures for more information.

Staff

The number of people employed by the group, converted to full-time positions, was 22 (15) at the end of the period. 11 (8) of the employees were men and 11 (7) were women.

Significant events after the end of the period

There are no significant events to report.

Acquisition of Zymetech ehf

On April 1, 2016, the group acquired 99.5 percent of the share capital in Zymetech ehf in the form of a non-cash issue of 20,905,942 new shares and 3,982,084 new warrants in Enzymatica, giving the group a controlling interest in Zymetech ehf. The acquisition price is calculated on the basis of Enzymatica's closing price on the Nasdaq First North at March 31, 2016, which was the most recent date prior to completion of the transaction. The closing price was SEK 3.45 per share at that date. The warrants are valued at SEK 0.97 per warrant using the Black & Scholes option pricing model at March 31, 2016. The purchase price for all shares of Zymetech is thus SEK 76,343 thousand, given that non-controlling interests are measured at fair value.

This acquisition gives Enzymatica international exclusive rights to a patent-protected enzyme, a key component of ColdZyme® Mouth Spray, as well as control over production of the enzyme, access to international research and development expertise and Zymetech's research portfolio. After the acquisition, Enzymatica will thus have exclusive rights in countries with patent protection until 2020 and a technological lead of several years over the rest of the world. The goodwill arising as a result of the transaction is attributable to acquired client relationships (which are not separable) and synergy effects expected from the merger of the operations of the group and Zymetech ehf.

An updated acquisition analysis has been prepared for the acquisition of Zymetech. The identified surplus values of intangible assets total SEK 7,533 thousand, which are amortized over the respective useful lives of these assets. The decrease in identified surplus values of intangible assets in comparison to the preliminary acquisition analysis described in the previous quarterly report is attributable to an adaptation to IFRS 3. This

resulted in one internal client relationship no longer being included in intangible assets. According to IFRS, a final acquisition analysis is to be prepared on December 31, 2016. The consideration in the acquisition analysis is divided as follows:

All amounts in SEK thousand	
Purchase price	76 343
Book value of equity	-7 110
	69 233
Total value adjustments (net)	7 533
Deferred tax liability	-1 507
Goodwill	63 207
Minority shareholding	355

Zymetech's fair value of acquired net assets, goodwill and impact on the group's cash flow can be seen in the table below:

Actual value, All amounts in SEK thousands	
Intangible assets	13 641
Property, plant & equipment	2 656
Financial assets	1 568
Inventories	736
Trade receivables	411
Other receivables	2 211
Cash and cash equivalents	27
Deferred tax liability	-1 507
Current interest-bearing liabilities	-4 392
Trade payables	-320
Other liabilities	-1 896
Acquired assets (net)	13 137
Goodwill	63 207
Total purchase price	76 343
Non cash issue	-75 988
Minority shareholding	-355
Cash and cash equivalents, acquired subsidiary	-27
Transaction expenses	1 491
Issue expenses	3 644
Acquired subsidiary, effect upon consolidated cash flow	5 108

The receivables acquired are measured at fair value.

The fair value of the non-controlling interests in Zymetech ehf, which is an unlisted company, is calculated using the consideration for the acquisition of 0.5% of Zymetech ehf.

The total transaction costs came in at SEK 2,023 thousand. Issue-related expenses totaled SEK 3,644 thousand (SEK 2,842 thousand after tax). SEK 1,491 thousand of the transaction costs impacted the 2016 loss (SEK 532 thousand 2015) for the group and were capitalized in the parent company. Issue expenses after tax have been charged to equity.

For the period from April to June 2016, Zymetech ehf has contributed revenue of SEK 1,076 thousand and a loss of SEK -2,707 to the consolidated income statement. The corresponding amounts contributed for the period from January to June 2016 were SEK 2,086 thousand in

revenue and SEK -4,677 thousand in loss.

Other information

Group

Enzymatica AB (publ) (corporate identity no. 556719-9244), with its head office in Lund, Sweden, is the parent company of the following subsidiaries: Zymetech ehf (corporate identity no. 6406830589), with its head office in Reykjavik, Iceland, Enzymatica Care AB (corporate identity no. 556701-7495), with its head office in Lund, Sweden, and Enzymatica North America Inc. (corporate identity no. 47-1030502), with its head office in Delaware, USA.

Accounting policies

This interim report has been prepared in compliance with IAS 34 Interim Financial Reporting. The consolidated financial statements have been prepared in compliance with the International Financial Reporting Standards (IFRS) as adopted by the EU and the Swedish Annual Accounts Act. The parent company's financial statements have been prepared in compliance with the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities. The recognition and measurement policies as well as the bases of estimates and judgements applied in the 2015 Annual Report have been applied in this interim report as well. New or revised IFRS standards that came into force in 2015 did not have any material impact on the group.

Segment reporting

Enzymatica's business currently only spans a single operating segment, Medical devices. Please see the income statement and balance sheet for reporting on this operating segment.

Information about risks and uncertainties

Enzymatica's business is exposed to several risks, both operational and financial risks. The operational risks mainly comprise uncertainty concerning product development, supplier agreements, product liability and distribution. For a more detailed description of the risks and uncertainties Enzymatica faces, please see the risk and sensitivity analysis in the 2015 Annual Report.

Audit

This report was not audited by the company's auditors.

2016 Annual General Meeting

The annual general meeting resolved in accordance with the proposal of the nominating committee to re-elect board members Lennart Nilsson, Marianne Dicander Alexandersson, Hans Pihl, Nils Siegbahn, Monica Wallter, Guðmundur Pálmason and Sigurgeir Guðlaugsson. Lennart Nilsson was re-elected as board chair.

Upcoming financial information

Interim report, Jul-Sep 2016	November 3, 2016
Year-end report 2016	February 16, 2017

The interim reports and annual report are available on Enzymatica's website www.enzymatica.se.

The Board of Directors and CEO hereby confirm that this interim report provides a true and fair view of the parent company's and group's business, financial position and results of operations, and describes material risks and uncertainties faced by the parent company and group companies.

Lund, July 18, 2016

Lennart Nilsson
Board Chair

Marianne Dicander Alexandersson
Board Member

Guðmundur Pálmason
Board Member

Sigurgeir Guðlaugsson
Board Member

Hans Pihl
Board Member

Nils Siegbahn
Board Member

Monica Wallter
Board Member

Fredrik Lindberg
CEO

For questions about this report, please contact:

Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com

Bengt Jöndell, Interim CFO, Enzymatica AB
Tel: +46 (0)703-77 71 70 | Email: bengt.jondell@enzymatica.com

Publication

Enzymatica AB (publ) is required by Swedish law (the Securities Market Act and/or the Financial Instruments Trading Act) to publish the information in this interim report. The information was submitted for publication on July 18, 2016 at 8:30 a.m.

Street address

Enzymatica AB (publ)

Corporate identity number: 556719-9244
Mailing address: Ideon Science Park, 223 70 LUND
Street address: Scheelevägen 19, Ideon, Lund
Phone: +46 (0)46-286 31 00 | info@enzymatica.se | www.enzymatica.se

Enzymatica is listed on the Nasdaq First North. The Company is traded under the ticker symbol ENZY and ISIN code SE0003943620. Enzymatica's certified advisor is Erik Penser Bankaktiebolag.

Consolidated Income Statement in Summary

All amounts in SEK thousand	Apr-Jun 2016	Apr-Jun 2015	Jan-Jun 2016	Jan-Jun 2015	Jan-Dec 2015
Operating income					
Net sales	4 892	3 086	13 304	10 047	27 912
Cost of goods sold	-1 788	-433	-5 079	-2 390	-8 486
Gross profit	3 104	2 653	8 225	7 657	19 426
Sales & Marketing expenses	-5 180	-5 531	-12 010	-13 996	-31 203
Administrative expenses	-8 112	-4 939	-12 466	-8 887	-20 906
Research and development costs	-7 824	-3 127	-9 672	-5 986	-10 898
Other operating income	298	-	454	-	9
Capitalized development expenditure	5 439	503	5 485	1 699	3 054
Operating profit/loss	-12 275	-10 441	-19 984	-19 513	-40 518
Profit/loss from financial items					
Interest income and similar profit/loss items	117	29	117	134	133
Interest expenses and similar profit/loss items	-651	-73	-1 041	-114	-445
Profit/loss after financial items	-12 809	-10 485	-20 908	-19 493	-40 830
Tax expenses	-	-	-	-	-
Profit/loss for the period	-12 809	-10 485	-20 908	-19 493	-40 830
Other comprehensive income:					
Total other comprehensive income, net of tax	0	0	0	0	0
Total comprehensive income for the period	-12 809	-10 485	-20 908	-19 493	-40 830
Share attributable to parent company shareholders	-12 809	-10 485	-20 908	-19 493	-40 830
Per share data	Apr-Jun 2016	Apr-Jun 2015	Jan-Jun 2016	Jan-Jun 2015	Jan-Dec 2015
Earnings per share, SEK (basic and diluted)	-0,20	-0,42	-0,47	-0,78	-1,64
Equity per share, SEK	1,78	1,73	1,78	1,73	0,88
Equity-asset ratio, %	87%	76%	87%	76%	50%
Number of outstanding shares	73 387 808	24 961 438	73 387 808	24 961 438	24 961 438
Average number of outstanding shares (basic and diluted)	64 214 332	24 961 438	44 587 885	24 961 438	24 961 438

Definitions of financial ratios

Earnings per share. Profit/loss for the period divided by average weighted number of shares

Equity-asset ratio. Equity divided by total assets.

Equity per share. Equity divided by number of shares at the end of the period.

Quarterly financial performance

All amounts in SEK thousand	Q2 2016	Q1 2016	Q4 2015	Q3 2015	Q2 2015
Net sales	4 892	8 412	11 052	6 813	3 086
Gross profit/loss	3 104	5 121	7 190	4 579	2 653
Gross margin in %	63%	61%	65%	67%	86%
Overhead costs	-21 116	-13 032	-18 324	-15 442	-13 597
Operating profit/loss	-12 275	-7 709	-11 134	-9 869	-10 441
Profit/loss for the period	-12 809	-8 099	-11 203	-10 134	-10 485
Cash flow	19 711	-866	-1 611	-13 762	-8 400

Consolidated Balance Sheet in Summary

All amounts in SEK thousand	2016-06-30	2015-06-30	2016-03-31	2015-12-31
Assets				
Intangible assets	95 523	12 710	13 683	13 776
Property, plant & equipment	3 051	288	244	276
Financial assets	2 409	13		
Inventories	10 837	13 760	9 984	11 410
Trade receivables	4 820	3 031	8 194	9 495
Other receivables	6 359	3 941	1 407	830
Cash and cash equivalents	26 910	23 438	7 199	8 065
Total assets	149 909	57 181	40 711	43 852
Equity and liabilities				
Equity	130 298	43 172	13 886	21 985
Current interest-bearing liabilities	11 481	-	15 112	10 939
Trade payables	3 404	11 019	7 173	5 980
Other liabilities	4 726	2 990	4 540	4 948
Total equity and liabilities	149 909	57 181	40 711	43 852

Consolidated statement of changes in equity

All amounts in SEK thousand	2016-06-30	2015-06-30	2016-03-31	2015-12-31
Opening balance	21 985	62 425	21 985	62 425
New share issue	59 995	-		
Issue expenses related to New share issue	-5 132	-		
Non cash issue in relation to acquisition of subsidiary	75 988	-		
Issue expenses related to Non cash issue	-2 842			
Effect of employee share ownership plan	63	240		390
Minority shareholding	355	-		
Exchange rate difference	794			
Profit/loss for the period	-20 908	-19 493	-8 099	-40 830
Closing balance	130 298	43 172	13 886	21 985

Consolidated cash flow statement

All amounts in SEK thousand	Apr-Jun 2016	Apr-Jun 2015	Jan-Jun 2016	Jan-Jun 2015	Jan-Dec 2015
Profit/loss after financial items	-12 809	-10 485	-20 908	-19 493	-40 830
Adjustments for non-cash items	811	461	1 505	516	1 550
Tax paid	-	-	-	-	-
Cash flow from operating activities before changes in working capital	-11 998	-10 024	-19 403	-18 977	-39 280
Changes in working capital	-3 148	2 127	-542	6 236	1 632
Cash flow from operating activities	-15 147	-7 897	-19 946	-12 741	-37 648
Acquisition of subsidiary	-5 108	-	-5 108	-	-
Capitalization of development expenditure	-5 439	-503	-5 485	-1 699	-3 053
Acquisition/disposal of property, plant & equipment	12	-	-155	-42	-93
Cash flow from investing activities	-10 535	-503	-10 748	-1 741	-3 146
New share issue	59 995	-	59 995	-	-
Transaction costs attributable to new share issue	-6 579	-	-6 579	-	-
Change in bank overdraft facilities	-8 023	-	-3 850	-	10 939
Cash flow from financing activities	45 393	0	49 566	0	10 939
Total cash flow for the period	19 711	-8 400	18 872	-14 482	-29 855
Cash and cash equivalents at start of period	7 199	31 838	8 065	37 920	37 920
Cash and cash equivalents at end of period	26 910	23 438	26 910	23 438	8 065

Parent company income statement

All amounts in SEK thousand	Apr-Jun 2016	Apr-Jun 2015	Jan-Jun 2016	Jan-Jun 2015	Jan-Dec 2015
Operating income					
Net sales	3 816	3 086	12 228	10 047	27 912
Cost of goods sold	-952	-433	-4 243	-2 390	-8 486
Gross profit	2 863	2 653	7 984	7 657	19 426
Sales & Marketing expenses	-4 835	-5 531	-11 665	-13 996	-31 203
Administrative expenses	-5 077	-4 939	-9 431	-8 887	-20 372
Research and development costs	-6 461	-3 127	-8 309	-5 986	-10 898
Other operating income	0	-	156	-	9
Capitalized development expenditure	5 439	503	5 485	1 699	3 054
Operating profit/loss	-8 070	-10 441	-15 779	-19 513	-39 984
Profit/loss from financial items					
Interest income and similar profit/loss items	-	29	-	112	117
Interest expenses and similar profit/loss items	-541	-73	-931	-114	-447
Profit/loss after financial items	-8 611	-10 485	-16 710	-19 515	-40 314
Tax expenses	-	-	-	-	-
Profit/loss for the period	-8 611	-10 485	-16 710	-19 515	-40 314

Parent company statement of comprehensive income

All amounts in SEK thousand	Apr-Jun 2016	Apr-Jun 2015	Jan-Jun 2016	Jan-Jun 2015	Jan-Dec 2015
Profit/loss for the period	-8 611	-10 485	-16 710	-19 515	-40 314
Other comprehensive income:	-	-	-	-	-
Total other comprehensive income, net of tax:	0	0	0	0	0
Total comprehensive income for the period	-8 611	-10 485	-16 710	-19 515	-40 314

Parent company balance sheet

All amounts in SEK thousand	2016-06-30	2015-06-30	2016-03-31	2015-12-31
Assets				
Intangible assets	18 937	12 709	13 683	13 776
Property, plant & equipment	211	288	244	276
Financial assets	78 135	111	111	111
Inventories	13 041	13 760	9 984	11 410
Trade receivables	4 308	3 031	8 194	9 495
Receivables from group companies	-	-	-	-
Other receivables	4 011	3 923	1 938	1 362
Cash and bank balances	26 559	23 386	7 122	7 988
Total assets	145 201	57 208	41 276	44 418
Equity and liabilities				
Equity	131 951	43 018	14 270	22 370
Current interest-bearing liabilities	7 126	-	15 112	10 939
Liabilities to group companies	191	191	191	191
Trade payables	2 889	11 019	7 173	5 980
Other liabilities	3 043	2 980	4 530	4 938
Total equity and liabilities	145 201	57 208	41 276	44 418